Alkem Laboratories has officially incorporated a wholly owned subsidiary named 'Alkem Pharmaceuticals Scientific Office FZ LLC' in Dubai Healthcare City, UAE, with a total investment of AED 3.67 million. The pharmaceutical company disclosed this strategic development through a regulatory filing under SEBI LODR Regulations, marking a significant milestone in its international expansion strategy.

Subsidiary Structure and Investment Details

The newly incorporated subsidiary has been established with comprehensive financial backing from its parent company. The investment structure demonstrates Alkem's commitment to establishing a strong presence in the Middle East pharmaceutical market.

Business Objectives and Operations

According to the regulatory disclosure, Alkem Pharmaceuticals Scientific Office FZ LLC has been incorporated to undertake manufacturing activities and obtain product registrations, excluding trading operations. This focused approach aligns with Alkem Laboratories' core pharmaceutical business and positions the subsidiary as a manufacturing and regulatory hub for the Middle East region.

Strategic Location Advantage

The establishment of operations in Dubai Healthcare City provides Alkem Laboratories with access to one of the Middle East's most prominent healthcare and pharmaceutical hubs. This strategic location serves as a gateway to the broader Middle East and North Africa (MENA) region, offering significant market expansion opportunities for the company's pharmaceutical products.

Regulatory Compliance and Timeline

The subsidiary was officially incorporated on February 4, 2026, and the disclosure was made to stock exchanges on March 30, 2026, in compliance with SEBI regulations. As a related party transaction due to the wholly owned subsidiary structure, this incorporation represents Alkem's systematic approach to international market entry while maintaining full operational control.

This development reinforces Alkem Laboratories' commitment to geographical diversification and establishes a foundation for capturing emerging opportunities in the Middle East pharmaceutical market.

Alkem laboratories has announced a key senior management appointment, strengthening its leadership team with an experienced sales professional. The pharmaceutical company disclosed the appointment under regulatory compliance requirements to stock exchanges.

Senior Management Appointment Details

The company has appointed Mr. Samsheer Kumar Deo to a senior management position effective from 27th March, 2026. The appointment was formally communicated to both BSE Limited and National Stock Exchange of India Limited as per regulatory requirements under SEBI LODR Regulations.

Professional Background and Experience

Mr. Samsheer Kumar Deo brings substantial industry experience to his new role at Alkem Laboratories. His professional credentials include:

• Experience: Over 29 years of experience in sales functions
• Educational Background: Bachelor of Science (B.Sc.) degree from Bhagalpur University, completed in 1992
• Key Strength: Instrumental in strengthening performance by handling sales function

Regulatory Compliance

The appointment disclosure was made pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company provided comprehensive details as required under Schedule III, Part A of the SEBI LODR Regulations and SEBI Master Circular bearing reference number HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30th January, 2026.

The disclosure was signed by Manish Narang, President – Legal, Company Secretary & Compliance Officer, and the information has been made available on the company's official website at www.alkemlabs.com for stakeholder access.